ReviewProtein & cell2010
Monoclonal antibodies - a proven and rapidly expanding therapeutic modality for human diseases.
Review in Protein & cell, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 60 citations in OpenAlex.
- Antibody-oligonucleotide conjugates: an emerging modality for precision RNA therapeutics.Antibody therapeutics · 2026Review
- A novel therapeutic monoclonal antibody targeting PZR demonstrates potent anti-metastatic efficacy in triple-negative breast cancer.Journal of translational medicine · 2026Article
- Diffusion, search and attack motions of antibodies.Communications biology · 2025Article
- Article
- Biodistribution and function of coupled polymer-DNA origami nanostructures.Scientific reports · 2023Article
- Article
- Development and Biophysical Characterization of a Humanized FSH-Blocking Monoclonal Antibody Therapeutic Formulated at an Ultra-High Concentration.bioRxiv : the preprint server for biology · 2023Article
- Optimizing a therapeutic humanized follicle-stimulating hormone-blocking antibody formulation by protein thermal shift assay.Annals of the New York Academy of Sciences · 2023Article
- Computational counterselection identifies nonspecific therapeutic biologic candidates.Cell reports methods · 2022Article
- Retrospective analysis of the preparation and application of immunotherapy in cancer treatment (Review).International journal of oncology · 2022Article
- Spatially Resolved Effects of Protein Freeze-Thawing in a Small-Scale Model Using Monoclonal Antibodies.Pharmaceutics · 2020Article
- Molecular and functional analysis of monoclonal antibodies in support of biologics development.Protein & cell · 2018Review
- "Magic Bullets" at the center stage of immune therapy: a special issue on therapeutic antibodies.Protein & cell · 2018Article
- Antibody-drug conjugates: recent advances in conjugation and linker chemistries.Protein & cell · 2018Review
- Preparation of monoclonal antibody against human KIAA0100 protein and Northern blot analysis of human KIAA0100 gene.Journal of pharmaceutical analysis · 2017Article
- Developments in therapy with monoclonal antibodies and related proteins.Clinical medicine (London, England) · 2017Review
- Efficient Qualitative and Quantitative Determination of Antigen-induced Immune Responses.The Journal of biological chemistry · 2016Article
- A comparative study on the physicochemical and biological stability of IgG1 and monoclonal antibodies during spray drying process.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2014Article
- Generation of human neutralizing monoclonal antibodies against the 2009 pandemic H1N1 virus from peripheral blood memory B lymphocytes.Cellular & molecular immunology · 2013Article
- Structural basis for treating tumor necrosis factor α (TNFα)-associated diseases with the therapeutic antibody infliximab.The Journal of biological chemistry · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The study of antibodies has been a focal point in modern biology and medicine since the early 1900s. However, progress in therapeutic antibody development was slow and intermittent until recently. The first antibody therapy, murine-derived murononab OKT3 for acute organ rejection, was approved by the US Food and Drug Administration (FDA) in 1986, more than a decade after César Milstein and Georges Köhler developed methods for the isolation of mouse monoclonal antibodies from hybridoma cells in 1975. As a result of the scientific, technological, and clinical breakthroughs in the 1980s and 1990s, the pace of therapeutic antibody discovery and development accelerated. Antibodies are becoming a major drug modality with more than two dozen therapeutic antibodies in the clinic and hundreds more in development. Despite the progress, need for improvement exists at every level. Antibody therapeutics provides fertile ground for protein scientists to fulfill the dream of personalized medicine through basic scientific discovery and technological innovation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.